Over the last 7 days, the market has remained flat, while in the past 12 months it has risen by 14%, with earnings expected to grow by 15% per annum over the next few years. For investors willing to ...

The pharmaceutical sector continues to stand out as a resilient and highly profitable corner of the market, even amid global ...

As global markets navigate a muted response to new U.S. tariffs and mixed economic signals, the Asian tech sector remains a focal point for investors seeking high growth opportunities. With market ...

Stocks like Wipro, Axis Bank, LTIMindtree, Indian Hotels, Lupin, Tracxn Technologies, Capital Small Finance Bank, Veranda ...

J.P. Morgan Research believes that the S&P 500 will close near 6,000 by year-end, aided by the double-digit growth in earnings.

On May 6, Arcutis reported first-quarter results showed loss of 20 cents a share, which slightly beat estimates. Its sales ...

Clearside Biomedical will divert all employees to a consulting status and halt research-and-development, allowing the eye-care biotechnology firm to conserve cash during a search for a deal or other ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

Onconetix said its shareholders will own 10% of the combined company upon completion of the deal, slated to close in the fourth quarter, while investors in Ocuvex, which is focused on developing ...

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

CRISPR Therapeutics is revolutionizing medicine with gene editing. Learn more about CRSP's breakthroughs, stock rally, and ...